The literature demonstrated that SGLT2i may be cost-effective compared to many antidiabetic therapies including DPP-4i, SU, TZD, AGI, insulin, and standard care (Economics and Policy in Diabetes)
Diabetes News
Tag: Type 2 Diabetes
New ABCD Resource: SGLT-2 inhibitors in people with type 2 diabetes
We hope that this document will help pragmatically support those involved in the day to day care of people with type 2 diabetes in the “here and now”, with the aim of maximizing the benefits and minimizing harm
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart Failure
Based on these findings, liraglutide should be considered suitable for patients with T2D with or without a history of NYHA functional class I to III HF (Journal of the American College of Cardiology)
FDA Proposes Broad Approach for Conducting Safety Trials for Type 2 Diabetes Medications
New Draft Guidance Considers Broader Evaluations Beyond Cardiovascular Outcomes Trials
Initial Glycemic Control and Care Among Younger Adults Diagnosed With Type 2 Diabetes
Adults with onset of type 2 diabetes at a younger age were less likely to achieve glycemic control at 1 year following diagnosis, suggesting the need for tailored care approaches to improve outcomes for this high-risk patient population (Diabetes Care)
Iron metabolism and type 2 diabetes mellitus: A meta‐analysis and systematic review
The elevated serum ferritin was one of the risk factors for type 2 diabetes, and soluble transferrin receptor‐to‐ferritin ratio was inversely related to the risk of type 2 diabetes. A systematic review showed that serum transferrin and hepcidin might be directly or indirectly related to the development of diabetes (Journal of Diabetes Investigation)
Record high two million people at risk of Type 2 Diabetes
Around two million people in England are at risk of developing Type 2 diabetes, the highest on record, according to new NHS figures
Hypoglycemia during Short-Term Intensive Insulin Therapy and Its Association with Long-Term Glycemic Remission in Patients with Newly Diagnosed Type 2 Diabetes
Mild hypoglycemic episodes during the continuing insulin dose reduction period indicate a long-term drug-free euglycemic remission in patients with newly diagnosed type 2 diabetes. However, the insulin dosage should be reduced even more quickly in the future treatment to decrease the potential harms (Journal of Diabetes Research)
Effect of Dapagliflozin on Atrial Fibrillation in Patients with Type 2 Diabetes Mellitus: Insights from the DECLARE-TIMI 58 Trial
Dapagliflozin decreased the incidence of reported episodes of AF/AFL adverse events in high-risk patients with T2DM. This effect was consistent regardless of the patients’ prior history of AF, ASCVD, or HF (circulation)
Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults
At diabetes onset, adults with latent autoimmune diabetes have a lower risk of microvascular complications followed by a later higher risk of complications than do adults with type 2 diabetes, secondary to worse glycaemic control (The Lancet Diabetes & Endocrinology)
Sodium‐Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis
Sodium‐glucose cotransporter 2 inhibitors protect against cardiovascular disease and death in diverse subsets of patients with type 2 diabetes mellitus regardless of cardiovascular disease history (Journal of the American Heart Association)
The Relationship between Self‐Monitored Blood Glucose Values and Glycated haemoglobin in Insulin‐treated Patients with Type 2 Diabetes
These data provide patients and clinicians information on the relationship between HbA1c and SMBG measurements in patients with type 2 DM, and support the value of frequent blood glucose measurements for assessing overall glycaemic control (Diabetic Medicine)
Daytime variability of postprandial glucose tolerance and pancreatic beta‐cell function using 12 hour profiles in persons with type 2 diabetes
There appears to be a shift in diurnal variation in glucose homeostasis and pancreatic beta‐cell function. Subjects had decreased glucose tolerance in response to the first and third meal of the day irrespective of glycaemic control. The variability in glucose tolerance was reflected by both quantitative and qualitative dysfunction of the pancreatic beta‐cell (Diabetic Medicine)
The cost of prevalent and incident cardiovascular disease in people with type 2 diabetes in Scotland: data from the Scottish Care Information–Diabetes Collaboration
Cardiovascular disease in people with type 2 diabetes places a significant financial burden on healthcare and the wider economy. Our results emphasize the financial consequences of cardiovascular disease prevention strategies (Diabetic Medicine)
Liraglutide as add‐on to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA‐ADD2SGLT2i, a 26‐week, randomized, double‐blind, placebo‐controlled trial
Liraglutide significantly improved glycaemic control compared to placebo in patients with type 2 diabetes, insufficiently controlled with SGLT2is with/without metformin, with no unexpected safety findings (Diabetes, Obesity and Metabolism)
Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D (Diabetes Care)
Time to Include Nonalcoholic Steatohepatitis in the Management of Patients With Type 2 Diabetes
It is time to include NASH in the management plan of patients with T2D in the same way as today it includes diabetic retinopathy or nephropathy (Diabetes Care)
Assessing the Risk for Gout With Sodium–Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes
Adults with type 2 diabetes prescribed an SGLT2 inhibitor had a lower rate of gout than those prescribed a GLP1 agonist. Sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout among adults with type 2 diabetes mellitus, although future studies are necessary to confirm this observation (Annals of Internal Medicine)
Five‐year effectiveness of bariatric surgery on disease remission, weight loss, and changes of metabolic parameters in obese patients with type 2 diabetes
Bariatric surgery was effective in weight loss, remission of diabetes, and dyslipidaemia in 5‐year post‐surgery (Diabetes/Metabolism Research and Reviews)
Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk
In SUSTAIN and PIONEER combined, glucagon‐like peptide‐1 analogue semaglutide showed consistent effects on MACE versus comparators across varying CV risk. No effect of semaglutide on MACE was observed in subjects with prior HF (Diabetes, Obesity and Metabolism)
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 45
- Next Page »
Glycosmedia is also available as an App: